Aurinia Pharmaceuticals to Release Third Quarter Financial Results and General Business Updates on November
8, 2018
Conference Call and webcast to follow
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH) (TSX:AUP) today announced that it will release its third quarter 2018 financial
results on Thursday, November 8, 2018, after the market closes. Aurinia’s management will host a conference call to discuss the
company’s third quarter 2018 financial results and provide a general business update.
The conference call and webcast is scheduled for November 8, 2018 at 4:30pm EDT. In order to participate in the conference call,
please dial +1-877-407-9170 (Toll-free U.S. & Canada). An audio webcast can be accessed under "News/Events” through the
“Investors” section of the Aurinia corporate website at
www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.
About Aurinia
Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted
patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing
voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS) and dry
eye syndrome (DES). The company is headquartered in Victoria, BC and focuses its development efforts globally. For further
information, see our website at
www.auriniapharma.com.
We seek safe harbor.
Investors:
Celia Economides
VP, Corporate & Public Affairs
IR@auriniapharma.com
or
Media:
Christopher Hippolyte, 212-364-0458
Christopher.hippolyte@inventivhealth.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20181025005203/en/